IL133974D0 - Derivatives of growth hormone and related proteins - Google Patents

Derivatives of growth hormone and related proteins

Info

Publication number
IL133974D0
IL133974D0 IL13397498A IL13397498A IL133974D0 IL 133974 D0 IL133974 D0 IL 133974D0 IL 13397498 A IL13397498 A IL 13397498A IL 13397498 A IL13397498 A IL 13397498A IL 133974 D0 IL133974 D0 IL 133974D0
Authority
IL
Israel
Prior art keywords
derivatives
growth hormone
related proteins
proteins
related
Prior art date
Application number
IL13397498A
Original Assignee
Bolder Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5251697P priority Critical
Application filed by Bolder Biotechnology Inc filed Critical Bolder Biotechnology Inc
Priority to PCT/US1998/014497 priority patent/WO1999003887A1/en
Publication of IL133974D0 publication Critical patent/IL133974D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5431IL-11
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5403IL-3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5409IL-5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5412IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5418IL-7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5425IL-9
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5428IL-10
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5437IL-13
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5443IL-15
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormones [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
IL13397498A 1997-07-14 1998-07-13 Derivatives of growth hormone and related proteins IL133974D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US5251697P true 1997-07-14 1997-07-14
PCT/US1998/014497 WO1999003887A1 (en) 1997-07-14 1998-07-13 Derivatives of growth hormone and related proteins

Publications (1)

Publication Number Publication Date
IL133974D0 true IL133974D0 (en) 2001-04-30

Family

ID=21978119

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13397498A IL133974D0 (en) 1997-07-14 1998-07-13 Derivatives of growth hormone and related proteins
IL133974A IL133974A (en) 1997-07-14 2000-01-10 Cysteine variant of growth hormone
IL200623A IL200623A (en) 1997-07-14 2009-08-27 Cysteine variant of beta interferon

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL133974A IL133974A (en) 1997-07-14 2000-01-10 Cysteine variant of growth hormone
IL200623A IL200623A (en) 1997-07-14 2009-08-27 Cysteine variant of beta interferon

Country Status (14)

Country Link
US (18) US6608183B1 (en)
EP (2) EP1881005B1 (en)
JP (2) JP2001510033A (en)
CN (1) CN1269805A (en)
AT (1) AT375363T (en)
AU (1) AU751898B2 (en)
BR (1) BR9812267B1 (en)
CA (1) CA2296770A1 (en)
DE (1) DE69838552T2 (en)
ES (1) ES2297889T3 (en)
HK (2) HK1028617A1 (en)
IL (3) IL133974D0 (en)
NZ (1) NZ502375A (en)
WO (1) WO1999003887A1 (en)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1608672A4 (en) * 2003-04-02 2007-11-21 Epimmune Inc Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
CN1269805A (en) * 1997-07-14 2000-10-11 博尔德生物技术公司 Derivatives of growth hormone and related proteins
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
CA2565375A1 (en) 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
CA2345138C (en) 1998-10-16 2009-12-15 Biogen, Inc. Polymer conjugates of interferon beta-1a and their uses
HU0200414A2 (en) 1998-10-16 2002-06-29 Biogen Inc Interferon-betha fusion proteins and uses
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1328295A2 (en) * 1999-08-27 2003-07-23 Maxygen Aps New interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
YU32402A (en) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Interferon gamma conjugates
CA2390292A1 (en) 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
WO2001036489A2 (en) * 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
AU782635B2 (en) * 1999-11-12 2005-08-18 Maxygen Holdings Ltd. Interferon gamma conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AU3153201A (en) * 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
AT428445T (en) 2000-02-11 2009-05-15 Bayer Healthcare Llc Cleaning factor vii or viia conjugate
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US7306931B2 (en) * 2000-05-16 2007-12-11 Bolder Biotechnology, Inc. Method for refolding proteins containing free cysteine residues
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
KR20030046411A (en) * 2000-09-08 2003-06-12 그리폰 테라퓨틱스, 인코포레이티드 'Pseudo'-Native Chemical Ligation
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1333036B1 (en) * 2000-10-16 2009-01-21 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
EP1334128A2 (en) * 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
CN101166753A (en) * 2003-01-31 2008-04-23 比奥根艾迪克Ma公司 Polymer conjugates of mutated neublastin
BR0207015A (en) * 2001-02-06 2004-07-06 Merck Patent Ges Mit Beschroen Eritropoientina modified (EPO) with reduced immunogenicity
SK11882003A3 (en) 2001-02-27 2004-03-02 Maxygen Aps New interferon beta-like molecules
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
JP4123856B2 (en) 2001-07-31 2008-07-23 日油株式会社 Bio-related substance modifier and method for producing polyoxyalkylene derivative
EP1501866A4 (en) 2001-10-02 2006-02-08 Genentech Inc Apo-2 ligand variants and uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002356990A1 (en) * 2001-11-20 2003-06-10 Pharmacia Corporation Chemically-modified human growth hormone conjugates
KR100467750B1 (en) * 2001-11-29 2005-01-24 씨제이 주식회사 Fusion protein having the enhanced in vivo activity of erythropoietin
US20080167238A1 (en) * 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003055526A2 (en) * 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
EP1477496A4 (en) * 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd Peg-conjugated pth or peg-conjugated pth derivate
BR0309576A (en) 2002-04-30 2005-02-09 Maxygen Holdings Ltd Factor vii (fvii) or factor viia (fviia) polypeptide variant, nucleotide sequence, expression vector, host cell, pharmaceutical composition, use of a variant, and method for treating a mammal having a disease or disorder in that clot formation is desirable
JP4574350B2 (en) 2002-06-24 2010-11-04 ジェネンテック, インコーポレイテッド APO-2 ligand / TRAIL variant and methods of use thereof
AU2003239774A1 (en) 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US20040121953A1 (en) * 2002-08-09 2004-06-24 Chirino Arthur J. Thrombopoiesis-stimulating proteins having reduced immunogenicity
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
KR101162908B1 (en) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EP1667708B9 (en) 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
AU2003300133B2 (en) 2002-12-31 2008-11-13 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
AU2003300139B2 (en) 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7771996B2 (en) 2003-03-20 2010-08-10 Bayer Healthcare Llc FVII or FVIIa variants
TW200510454A (en) 2003-04-15 2005-03-16 Smithkline Beecham Corp Conjugates comprising human IL-18 and substitution mutants thereof
WO2004099245A1 (en) * 2003-05-05 2004-11-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Stabilised interferon-ϝ
SI1644504T1 (en) 2003-06-19 2010-06-30 Bayer Healthcare Llc Factor vii or viia gla domain variants
US7785580B2 (en) 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
US7404957B2 (en) * 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
AT481420T (en) * 2003-10-10 2010-10-15 Novo Nordisk As Il-21 derivatives
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
AU2004297228A1 (en) 2003-12-03 2005-06-23 Nektar Therapeutics Al, Corporation Method of preparing maleimide functionalized polymers
CN1902311A (en) * 2003-12-31 2007-01-24 森托科尔公司 Novel recombinant proteins with n-terminal free thiol
PT1706428E (en) 2004-01-22 2009-12-29 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
NZ548255A (en) * 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
AU2005245918A1 (en) 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
CN101031323A (en) * 2004-07-16 2007-09-05 尼克塔治疗亚拉巴马公司 Conjugates of gm-csf moiety and a polymer
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
CA2577999A1 (en) * 2004-08-31 2006-03-09 Rory F. Finn Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
AT542920T (en) 2004-12-22 2012-02-15 Ambrx Inc Modified human growth hormone
SG158149A1 (en) * 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0518661A2 (en) 2004-12-22 2008-12-02 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
MX2007007581A (en) 2004-12-22 2007-07-24 Ambrx Inc Compositions of aminoacyl-trna synthetase and uses thereof.
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2006089228A2 (en) 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
AU2006299901A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
CA2609205A1 (en) * 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
KR100694994B1 (en) * 2005-06-13 2007-03-14 씨제이 주식회사 Human Granulocyte-Colony Stimulating Factor Isoforms
EP2476428B1 (en) 2005-06-29 2013-08-21 Yeda Research and Development Co. Ltd. Recombinant interferon alpha 2 (IFN alpha 2) mutants
KR100735784B1 (en) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof
KR20080079643A (en) 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 Methods and compositions comprising non-natural amino acids
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7659250B2 (en) 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
AT543833T (en) * 2005-12-22 2012-02-15 Janssen Biotech Inc Bmp-7 variants compositions, methods and uses
AT555125T (en) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin 12p40 variants with improved stability
PT1966245E (en) 2005-12-30 2011-08-31 Merck Patent Gmbh Anti-cd19 antibodies with reduced immunogenicity
ES2546282T3 (en) * 2006-02-14 2015-09-22 Novo Nordisk Health Care Ag Polypeptide coupling at the C-terminal end
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
CN101495536B (en) 2006-05-26 2012-03-07 益普生制药股份有限公司 Methods for site-specific pegylation
EP2056852A4 (en) * 2006-07-27 2010-01-13 Centocor Ortho Biotech Inc Bmp-7 variant compositions, methods and uses
MX2009002526A (en) 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
DK2615108T3 (en) * 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
MX2009002460A (en) 2006-09-08 2009-03-20 Ambrx Inc Hybrid suppressor trna for vertebrate cells.
US8475784B2 (en) 2006-10-26 2013-07-02 Novo Nordisk A/S IL-21 variants
WO2008065372A2 (en) * 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
AR065083A1 (en) * 2007-02-02 2009-05-13 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2008137574A1 (en) 2007-05-01 2008-11-13 Biogen Idec Ma Inc. Compositions and methods for increasing vascularization
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
ES2551123T3 (en) 2007-06-12 2015-11-16 Ratiopharm Gmbh Improved process for the production of nucleotide sugars
CA2701032A1 (en) * 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
MX338336B (en) 2007-11-20 2016-04-07 Ambrx Inc Modified insulin polypeptides and their uses.
WO2009073977A1 (en) * 2007-12-13 2009-06-18 Biovectra Inc. Polypeptides modified by protein trans-splicing technology
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
CN103694337B (en) 2008-02-08 2016-03-02 Ambrx公司 Modified leptin polypeptides and uses thereof
CN101525381B (en) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 Novel recombinant consensus interferon and construction of a high-efficiency expression vector thereof
EP2294087B1 (en) 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin antibodies and methods of use
US20110171168A1 (en) * 2008-05-13 2011-07-14 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
EP2274325A4 (en) * 2008-05-13 2011-05-25 Nora Therapeutics Inc Human g-csf analogs and methods of making and using thereof
AU2009274076C1 (en) 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
US8865868B2 (en) * 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
JP5709754B2 (en) 2008-09-26 2015-04-30 アンブルックス,インコーポレイテッドAmbrx,Inc. Microorganisms and vaccines that rely on replication with unnatural amino acids
BRPI0919403A2 (en) 2008-09-26 2017-09-26 Ambrx Inc modified animal erythropoietin polypeptides and their uses
WO2010056981A2 (en) 2008-11-13 2010-05-20 Massachusetts General Hospital Methods and compositions for regulating iron homeostasis by modulation bmp-6
US20100221236A1 (en) * 2008-12-05 2010-09-02 Satish Singh Mutants of Staphylokinase Carrying Amino and Carboxy-Terminal Extensions for Polyethylene Glycol Conjugation
JP5816097B2 (en) * 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP5781501B2 (en) 2009-04-22 2015-09-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Antibody fusion protein with modified FcRn binding site
JP5751641B2 (en) 2009-05-06 2015-07-22 ヤンセン バイオテツク,インコーポレーテツド melanocortin receptor binding conjugate
EP2461831B1 (en) * 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
WO2011037896A2 (en) * 2009-09-25 2011-03-31 Vybion, Inc. Polypeptide modification
MX344382B (en) 2009-10-23 2016-12-14 Amgen Inc * Vial adapter and system.
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
MX349301B (en) 2009-12-21 2017-07-21 Ambrx Inc Modified bovine somatotropin polypeptides and their uses.
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
CN106139158A (en) * 2010-01-22 2016-11-23 诺沃—诺迪斯克保健股份有限公司 The growth hormone that in vivo efficacy extends
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
BR112012031121A2 (en) 2010-06-07 2016-11-01 Amgen Inc drug delivery device
EP2595661A1 (en) * 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522A8 (en) 2010-08-17 2017-12-26 Ambrx Inc "modified relaxin polypeptides comprising a non-naturally encoded amino acid, use, method of preparation as well as nucleic acid encoding them"
KR20140016262A (en) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
AU2012207456C1 (en) 2011-01-18 2017-05-04 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
JP2014507423A (en) * 2011-02-01 2014-03-27 フェイト セラピューティクス,インコーポレイテッド Cardiotrophin-related molecules for enhanced therapeutic agents
MX341790B (en) 2011-03-31 2016-09-02 Amgen Inc Vial adapter and system.
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
JP6038884B2 (en) 2011-04-20 2016-12-07 アムゲン・インコーポレーテッド Automatic injection device
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
CA2840409A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
EP3335747A1 (en) 2011-10-14 2018-06-20 Amgen Inc. Injector and method of assembly
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
CN103509102B (en) * 2012-06-15 2015-07-22 郭怀祖 Wild type human growth hormone mutant
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
SI2890402T1 (en) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
EP2922590A1 (en) 2012-11-21 2015-09-30 Amgen Inc. Drug delivery device
EP2958584A1 (en) 2013-02-20 2015-12-30 Yeda Research and Development Co., Ltd. Interferon treatment targeting mutant p53 expressing cells
JP2016511275A (en) 2013-03-11 2016-04-14 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone compounds
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CN105263514B (en) 2013-03-15 2019-04-26 本质生命科学有限公司 Anti- hepcidin antibody and application thereof
US20150374919A1 (en) 2013-03-22 2015-12-31 Amgen Inc. Injector and method of assembly
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
JP2016519108A (en) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド Method for using interleukin-10 for the treatment of diseases and disorders
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
AU2014257906A1 (en) * 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015000585A1 (en) 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
BR112016002845A2 (en) 2013-08-12 2017-09-12 Genentech Inc compositions and methods for treating complement-associated conditions
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
EP3055298A1 (en) 2013-10-11 2016-08-17 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
JP2016538096A (en) 2013-10-24 2016-12-08 アムジエン・インコーポレーテツド Drug delivery system with temperature sensing control
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
CN106536562A (en) 2014-05-01 2017-03-22 泰华制药澳大利亚公司 Combination of lenalidomide or pomalidomide and CD38 antibody-attenuated interferon-alpha constructs, and the use thereof
CN106413779A (en) 2014-05-07 2017-02-15 安姆根有限公司 Autoinjector with shock reducing elements
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2015187797A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Controllable drug delivery system and method of use
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
JP2017530817A (en) 2014-10-14 2017-10-19 アムジエン・インコーポレーテツド Drug injection device with visual and audible indicators
CN107106655A (en) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 The method that disease and illness are treated using interleukin 10
CN110078814A (en) 2014-10-24 2019-08-02 百时美施贵宝公司 FGF-21 polypeptide of modification and application thereof
SG11201703251TA (en) * 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
JP2017538511A (en) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド Drug delivery device with proximity sensor
JP2017538512A (en) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド Drug delivery device including live button or user interface field
US20180036476A1 (en) 2015-02-17 2018-02-08 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
JP2018516913A (en) 2015-05-28 2018-06-28 アルモ・バイオサイエンシーズ・インコーポレイテッド Pegylated interleukin-10 for use in cancer therapy
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
KR20180069841A (en) 2015-10-09 2018-06-25 바이오니즈, 엘엘씨 Adjustment of gamma-C-cytokine activity
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US20180318526A1 (en) 2015-12-09 2018-11-08 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
EP3429663A1 (en) 2016-03-15 2019-01-23 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US20190192766A1 (en) 2016-04-29 2019-06-27 Amgen Inc. Drug Delivery Device with Messaging Label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
CA3018426A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988A1 (en) 2016-05-16 2019-03-27 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
KR20190115049A (en) 2017-02-08 2019-10-10 브리스톨-마이어스 스큅 컴퍼니 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
AU2018220538A1 (en) 2017-02-17 2019-06-27 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
AU2018231107A1 (en) 2017-03-06 2019-08-01 Amgen Inc. Drug delivery device with activation prevention feature
AU2018230546A1 (en) 2017-03-07 2019-08-22 Amgen Inc. Needle insertion by overpressure
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
WO2018172219A1 (en) 2017-03-20 2018-09-27 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
SG11201907676PA (en) 2017-03-28 2019-09-27 Amgen Inc Plunger rod and syringe assembly system and method
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. Wearable injector with sterile adhesive patch
US20190060562A1 (en) 2017-08-22 2019-02-28 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019051073A1 (en) 2017-09-08 2019-03-14 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
WO2019099322A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
WO2019130344A1 (en) * 2017-12-27 2019-07-04 Council Of Scientific And Industrial Research A polypeptide exhibiting granulocyte-colony stimulating factor activity

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4921699A (en) 1983-06-01 1990-05-01 Hoffman-La Roche Inc. Polypeptides having interferon activity
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method of producing erythropoietin
MX9203641A (en) 1983-12-16 1992-07-01 Genentech Inc Recombinant gamma interferons having enhanced stability and biotechnological methods of making.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
US5908763A (en) * 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
RU2130493C1 (en) * 1984-07-06 1999-05-20 Новартис Аг Method of preparing protein exhibiting gm-csf activity of pimates
US5895646A (en) * 1984-09-19 1999-04-20 Novartis Corporation Isolated native primate GM-CSF protein
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
DK151585D0 (en) * 1985-04-03 1985-04-03 Nordisk Gentofte DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3540076A1 (en) 1985-11-12 1987-05-14 Boehringer Mannheim Gmbh A process for the stabilization of creatine kinase
DK203187A (en) 1986-04-22 1987-10-23 Immunex Corp Human G-CSF Protein Expression
US5681720A (en) 1986-12-23 1997-10-28 Kyowa Hakko Co., Ltd. DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JPH01132598A (en) 1987-10-14 1989-05-25 Pitman Moore Inc Method for promoting formation of intramolecular disulfide in recombinant protein included in denaturant solution
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
AU3532289A (en) 1988-05-06 1989-11-29 Genentech Inc. Novel bovine granulocyte-macrophage colony stimulating factor variant
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ES2154627T3 (en) 1988-08-24 2001-04-16 American Cyanamid Co Stabilization of somatotropins by modification of cysteine ​​residues using site directed mutagenesis or chemical derivatization.
US5223407A (en) 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
JP2517100B2 (en) 1989-03-08 1996-07-24 協和醗酵工業株式会社 Human granulocyte colony - purification of proteins having stimulating factor activity
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5130418A (en) 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
JPH04164098A (en) 1990-03-07 1992-06-09 Kirin Amgen Inc Chemically modified granulocyte colony stimulating factor derivative
US5235043A (en) 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
DK97190D0 (en) 1990-04-19 1990-04-19 Novo Nordisk As oxidation-stable detergent enzymes
AT163431T (en) * 1990-05-04 1998-03-15 American Cyanamid Co Stabilization of somatotropin by modifying cysteinsresten
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
DE4113750A1 (en) 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Improve the natural regeneration in the secretion of disulfide-bonded proteins
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1994001453A1 (en) 1992-07-02 1994-01-20 Pitman-Moore, Inc. A process for recovering a recombinant protein, in biologically active form, from a solution containing inactive protein
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AT238421T (en) 1992-11-24 2003-05-15 Searle & Co Interleukin-3 (IL-3) polypeptides mith more mutations
JPH08506095A (en) * 1992-11-25 1996-07-02 アムジェン ボールダー インコーポレイテッド Modified insulin-like growth factor
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5441734A (en) * 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
WO1994022466A1 (en) * 1993-04-07 1994-10-13 Synergen, Inc. Methods of using insulin-like growth factor binding proteins
EP0626448A3 (en) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Process for preparing and purifying alpha-interferon
JPH09504174A (en) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ,インク. Chimeric protein containing a protease nexin 1 mutant
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US6207640B1 (en) 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
WO1995032003A1 (en) 1994-05-24 1995-11-30 Amgen Boulder Inc. Modified insulin-like growth factors
ITFI940106A1 (en) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Hybrid Molecule Formula gm-csf-the-EPO or EPO-the-gm-csf for stimolaz ion erythropoietic
CA2172273A1 (en) 1994-07-29 1996-02-15 Geert Maertens Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DK0785948T3 (en) 1994-10-13 2003-08-04 Amgen Inc Analogues of keratinocyte growth factor
JPH11504316A (en) 1995-04-05 1999-04-20 ザ ピコワー インスティテュート フォア メディカル リサーチ Agents and methods of use thereof that binds to a progressive glycosylation endproducts
EP0833665A1 (en) 1995-05-16 1998-04-08 Prizm Pharmaceuticals, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
DE19535853C2 (en) * 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Variants of recombinant human interferon-gamma, a process for their preparation and their use
DK1568772T3 (en) * 1995-09-21 2010-10-18 Genentech Inc Variants of human growth hormone
AU702975B2 (en) 1995-09-22 1999-03-11 Immunomedics Inc. Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
DE69632062T2 (en) 1995-11-02 2004-11-18 Schering Corp. Continuous low-dose cytokine-infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
BR9606270A (en) * 1996-12-18 1998-09-22 Univ Minas Gerais Process for the production of recombinant human protein interferon beta-cis protein and recombinant human interferon beta-cis
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
DE19717864C2 (en) * 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Human recombinant interferon-beta, process for its preparation and its use
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7495087B2 (en) * 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
CN1269805A (en) * 1997-07-14 2000-10-11 博尔德生物技术公司 Derivatives of growth hormone and related proteins
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6756491B2 (en) * 1998-01-09 2004-06-29 The Salk Institute For Biological Studies Steroid-activated nuclear receptors and uses therefor
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2359345A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
JP4617533B2 (en) * 2000-03-14 2011-01-26 ソニー株式会社 Information providing apparatus and method, information processing apparatus and method, and program storage medium
US7306931B2 (en) 2000-05-16 2007-12-11 Bolder Biotechnology, Inc. Method for refolding proteins containing free cysteine residues
AU2725202A (en) 2000-12-01 2002-06-11 Cornell Res Foundation Inc Animal model for flaviviridae infection
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US20030233694A1 (en) * 2002-06-25 2003-12-25 Michael Wescombe-Down Protective swimsuit incorporating an electrical wiring system
CA2497777A1 (en) 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
JP4507099B2 (en) 2004-07-09 2010-07-21 エルピーダメモリ株式会社 Semiconductor device module
CA2577999A1 (en) 2004-08-31 2006-03-09 Rory F. Finn Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
KR20100014215A (en) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 New protein conjugates and methods for their preparation
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
AU2014286998A1 (en) 2013-07-11 2016-02-11 The Scripps Research Institute Coiled coil immunoglobulin fusion proteins and compositions thereof
US9506540B1 (en) 2015-12-29 2016-11-29 Honda Motor Co., Ltd. Pedal apparatus

Also Published As

Publication number Publication date
US7345149B2 (en) 2008-03-18
US7214779B2 (en) 2007-05-08
US8618256B2 (en) 2013-12-31
ES2297889T3 (en) 2008-05-01
US6608183B1 (en) 2003-08-19
US20050227330A1 (en) 2005-10-13
US20040230040A1 (en) 2004-11-18
US20090060863A1 (en) 2009-03-05
US20080317713A1 (en) 2008-12-25
US20110250169A1 (en) 2011-10-13
CN1269805A (en) 2000-10-11
US20050096461A1 (en) 2005-05-05
JP2009096810A (en) 2009-05-07
US7964184B2 (en) 2011-06-21
HK1028617A1 (en) 2008-08-01
US20140163204A1 (en) 2014-06-12
US7232885B2 (en) 2007-06-19
IL200623A (en) 2012-02-29
US20170369547A1 (en) 2017-12-28
DE69838552T2 (en) 2008-05-21
US7148333B2 (en) 2006-12-12
AU751898B2 (en) 2002-08-29
US7314921B2 (en) 2008-01-01
HK1116497A1 (en) 2014-01-10
US20030166865A1 (en) 2003-09-04
IL200623D0 (en) 2011-07-31
EP1012184B1 (en) 2007-10-10
EP1012184A1 (en) 2000-06-28
DE69838552D1 (en) 2007-11-22
US20040265269A1 (en) 2004-12-30
US7345154B2 (en) 2008-03-18
BR9812267B1 (en) 2013-11-26
US7959909B2 (en) 2011-06-14
AU8300098A (en) 1999-02-10
EP1881005B1 (en) 2013-04-03
US10329337B2 (en) 2019-06-25
NZ502375A (en) 2001-11-30
US20040175800A1 (en) 2004-09-09
WO1999003887A1 (en) 1999-01-28
US20080219950A1 (en) 2008-09-11
US7795396B2 (en) 2010-09-14
US7309781B2 (en) 2007-12-18
IL133974A (en) 2010-05-17
US20030162949A1 (en) 2003-08-28
JP2001510033A (en) 2001-07-31
US20050214254A1 (en) 2005-09-29
BR9812267A (en) 2001-12-18
US20040175356A1 (en) 2004-09-09
US7253267B2 (en) 2007-08-07
US20040214287A1 (en) 2004-10-28
EP1012184A4 (en) 2003-03-26
AT375363T (en) 2007-10-15
CA2296770A1 (en) 1999-01-28
US20050107591A1 (en) 2005-05-19
US7732572B2 (en) 2010-06-08
EP1881005A1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
DK0781329T3 (en) Overexpression of mammalian and viral proteins
DE69534629D1 (en) Derivatives of zinc finger proteins and methods
US6114148C1 (en) High level expression of proteins
DK1568772T3 (en) Variants of human growth hormone
DE69841549D1 (en) Process and preparations for destruction of certain proteins
DK0911342T3 (en) New protein and process for its preparation
AU698790B2 (en) Stabilizing solutions for proteins and peptides
AU5155398A (en) Anti-ccr5 antibodies and methods of use therefor
PL340589A1 (en) Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
AU5159598A (en) Delivery construct for antisense nucleic acids and methods of use
AT365808T (en) Transport proteins and its uses
AU4259097A (en) Heterocyclic thioesters and ketones
PL194499B1 (en) Superabsorptive material and method of making same
HU0001811A3 (en) Bone paste and method for preparation thereof
AU5721798A (en) Human mage-like protein
AU6270998A (en) Method of enhancing hair growth
PL329875A1 (en) Derivatives of carbolin
EP1007562A4 (en) TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
PL335974A1 (en) Method of orally administering proteins
PL329195A1 (en) Derivatives of 6-phenylpyridol-2-amine
AU2122897A (en) Antimicrobial peptides and methods of use
PL339053A1 (en) Novel derivatives of 2-oxy-pyrimidyn-4-one and pyrimidin-4-thione as fungicides
AU2422497A (en) Soluble divalent and multivalent heterodimeric analogs of proteins
PL194689B1 (en) Derivatives of quinazoline
IL130396D0 (en) OB fusion protein compositions and methods